When it was announced that Nintendo was going to be released a fighting game with motion controls called Arms, many were concerned that the response wouldn’t be up to par. Based on early impressions, however, both the game and the controls seem to be performing well. This should come as a relief to fans of the Switch who might have been worried that its rise to fame might be derailed.
It’s no secret that the Nintendo Switch is on Cloud 9 right now, with the console breaking records at every turn and enthusiasm for ownership still sky high. However, even the smallest details can turn players off from a product and wonky motion controls could be a deal breaker for many. Fortunately, Kotaku and publications like it have judged that such concerns might be unwarranted.
Now, it’s worth noting that this is one game and the controls are about as straightforward as they can be. Even so, critics are still impressed by how well the characters respond to movements in order to perform three basic attacks in Arms.
For those who don’t know, Arms is basically a fighting game where players control characters who use extendable extremities to fight. Players can use both the normal controller scheme or the Joy-Con motion control and it was the latter that the reviewers focused on.
Suffice it to say, most of those who were lucky enough to test the game and the controls were surprised at how good it was. Granted, much of the excellence in the controls had a lot to do with how smart the developers were at taking advantage of the gyro-sensors, IGN notes. Whether it is punching, blocking or throwing, everything worked smoothly.
Of course, getting the hang of the controls does involve a learning curve, so players shouldn’t assume that the game will work perfectly for them without some practice. All in all, the Switch and Arms seem to perform admirably in an area where so much could have gone wrong. Players will know soon enough when the game comes out on June 16th.


Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand
NASA Resumes Cygnus XL Cargo Docking with Space Station After Software Fix
Neuralink Expands Brain Implant Trials with 12 Global Patients
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium
Kennedy Sets September Deadline to Uncover Autism Causes Amid Controversy
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets
CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market
FDA Pilot Program Eases Rules for Nicotine Pouch Makers
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand 



